Optibrium Adds Augmented Intelligence for Compound Design to its StarDrop Small Molecule Drug Discovery Software

Optibrium Ltd, a leading developer of software for drug discovery, today announced the release of the latest version of StarDrop™, its comprehensive software platform for small molecule design, optimisation and data analysis. More than 160 organisations currently use StarDrop, including many of the world’s leading pharmaceutical companies. The new release introduces Inspyra™, a module that dynamically learns from chemists’ expert knowledge and feedback to guide automated compound design methods, creating a powerful ‘augmented intelligence’ to accelerate the discovery of high-quality drug candidates.

The impact of ‘generative chemistry’ algorithms for automated compound design is often limited in practice by a lack of alignment with chemists’ existing workflows and know-how, resulting in irrelevant compound suggestions. StarDrop’s new Inspyra module addresses this limitation by combining exploratory capabilities of automated compound design with chemists’ expertise, helping to focus on the most relevant chemistry spaces and suggest optimisation strategies with the highest potential for project success.

Inspyra has been developed in collaboration with global pharmaceutical companies, and has already been applied successfully across several hit-to-lead and lead optimisation projects. The module leverages StarDrop’s predictive modelling and data visualisation capabilities, multi-parameter optimisation, and 2D and 3D structure-activity-relationship (SAR) analysis, delivering a comprehensive solution for small molecule optimisation that reduces cost and time while increasing the chance of successful drug discovery.

“Having led groups at Novartis and MSD, access to an intuitive tool like the new Inspyra module for StarDrop would have been invaluable. While I am a firm believer in the benefits of automated compound idea generation, time and time again, colleagues were frustrated looking at compound suggestions that were not relevant to them for one reason or another. Inspyra is the first approach to address this challenge, and we are proud to release this new StarDrop version with unprecedented automated compound design support.” 

Dr Peter Hunt, Director of Computational Chemistry at Optibrium

For further information on Optibrium, contact [email protected] or call +44 1223 815900.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Optibrium Ltd.. (2023, July 11). Optibrium Adds Augmented Intelligence for Compound Design to its StarDrop Small Molecule Drug Discovery Software. News-Medical. Retrieved on May 05, 2024 from https://www.news-medical.net/news/20220302/Optibrium-Adds-Augmented-Intelligence-for-Compound-Design-to-its-StarDrop-Small-Molecule-Drug-Discovery-Software.aspx.

  • MLA

    Optibrium Ltd.. "Optibrium Adds Augmented Intelligence for Compound Design to its StarDrop Small Molecule Drug Discovery Software". News-Medical. 05 May 2024. <https://www.news-medical.net/news/20220302/Optibrium-Adds-Augmented-Intelligence-for-Compound-Design-to-its-StarDrop-Small-Molecule-Drug-Discovery-Software.aspx>.

  • Chicago

    Optibrium Ltd.. "Optibrium Adds Augmented Intelligence for Compound Design to its StarDrop Small Molecule Drug Discovery Software". News-Medical. https://www.news-medical.net/news/20220302/Optibrium-Adds-Augmented-Intelligence-for-Compound-Design-to-its-StarDrop-Small-Molecule-Drug-Discovery-Software.aspx. (accessed May 05, 2024).

  • Harvard

    Optibrium Ltd.. 2023. Optibrium Adds Augmented Intelligence for Compound Design to its StarDrop Small Molecule Drug Discovery Software. News-Medical, viewed 05 May 2024, https://www.news-medical.net/news/20220302/Optibrium-Adds-Augmented-Intelligence-for-Compound-Design-to-its-StarDrop-Small-Molecule-Drug-Discovery-Software.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Optibrium’s Quantum Mechanics and Machine Learning Methods Predict Routes of Drug Metabolism